Medicare Compliance & Reimbursement - 2015 Issue 28
Part B Coding Coach: CMS Proposal Would Dramatically Alter Drug Testing Codes
Subscribe or sign in to view the full article.
Article Overview
This article explains a CMS proposal that would significantly change Medicare drug testing reporting for calendar year 2016 and contrasts it with the CPT toxicology framework used for non-Medicare payers. It is relevant to coders, billers, laboratorians, compliance staff, and clinicians who work with drug-of-abuse testing, because it summarizes the policy context, the major code-set categories involved, and the concerns raised by stakeholders at a CMS public meeting. The discussion focuses on the broad structure of the proposed coding approach, the role of related federal agencies, and the types of feedback CMS received before final pricing decisions.
Why This Topic Matters
Drug testing reimbursement and reporting can change quickly when CMS revises Medicare-specific code requirements. Understanding the proposal and the surrounding stakeholder response helps practices assess how federal policy may affect laboratory billing, coverage, and documentation workflows.
Article Sections
-
Recall 2015 CMS Plan
Background on CMS’s 2015 approach to Medicare drug testing and the code families already in use at that time. This section sets up the comparison between Medicare reporting and broader CPT toxicology coding.
-
Compare to CPT® 2015 Options
An overview of the CPT toxicology structure referenced for non-Medicare drug-of-abuse testing. The section explains the general organization of presumptive, definitive, and therapeutic drug testing categories.
-
Sneak a Peek at CMS 2016 Drug-Test Coding Proposal
A summary of CMS’s proposed Medicare coding approach for calendar year 2016 and the agencies involved in the recommendation. The section also introduces the types of comments and concerns raised by meeting participants.
-
Stakeholder response
Reactions from professional organizations and meeting speakers regarding the proposed structure. This section covers broad concerns about reporting detail, payment accuracy, and policy implementation.
-
Counter offer
Alternative suggestions offered by stakeholders in response to the CMS proposal. The discussion remains at a high level and reflects differing views on how drug testing should be grouped for reporting.
-
Wait and see
A brief note on the timeline for CMS pricing decisions and the opportunity for public comment. This section indicates the next steps in the regulatory process.
What You Will Learn
- How CMS proposed to restructure Medicare drug testing coding for 2016
- How the article contrasts Medicare-specific reporting with CPT toxicology categories
- What broad concerns stakeholders raised about the proposed approach
- Which organizations and federal agencies were involved in the discussion
- What the article says about the timing of pricing and comment opportunities
Who Should Read This
- Medical coders
- Medical billers
- Clinical laboratory staff
- Compliance professionals
- Physicians and ordering clinicians
- Practice administrators
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com